# OnCo record nct06378177 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06378177/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06378177", "NCT06378177" ;
  schema:name "A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)"@en ;
  schema:description "A phase 2 trial of Toripalimab, Paclitaxel / nab-paclitaxel in head and neck squamous cell carcinoma, run by Lyvgen Biopharma Holdings Limited, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06378177/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06378177> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2024-06-21" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/recurrent-metastatic-hnscc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/lvgn6051/> ;
  onco:companies <https://onco.cc/companies/lyvgen-biopharma/> .